Clinical Trials Logo

Liposarcoma, Myxoid clinical trials

View clinical trials related to Liposarcoma, Myxoid.

Filter by:

NCT ID: NCT06083883 Suspended - Synovial Sarcoma Clinical Trials

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Start date: March 27, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.

NCT ID: NCT06048705 Terminated - Neoplasms Clinical Trials

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Start date: March 9, 2021
Phase: Phase 1
Study type: Interventional

The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A*02:01, HLA-A*02:05 and/or HLA A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or Cancer testis antigen 2 (LAGE 1a) positive previously treated metastatic Non-Small Cell Lung Cancer (NSCLC) and previously treated, advanced (metastatic or unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma SS/MRCLS.

NCT ID: NCT05993299 Active, not recruiting - Neoplasms Clinical Trials

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Start date: December 31, 2019
Phase: Phase 2
Study type: Interventional

This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

NCT ID: NCT05943990 Terminated - Neoplasms Clinical Trials

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Start date: December 21, 2020
Phase: Phase 1
Study type: Interventional

To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1 and/or Cancer testis antigen 2 (LAGE-1a) positive, previously treated, advanced (metastatic or unresectable) Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCLS).

NCT ID: NCT05492682 Recruiting - Colorectal Cancer Clinical Trials

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Start date: February 2, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

NCT ID: NCT05266196 Enrolling by invitation - Ewing Sarcoma Clinical Trials

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Start date: January 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This rollover protocol allows continued access to seclidemstat (SP-2577) for patients who are still receiving clinical benefit on completed or closed Salarius sponsored studies.

NCT ID: NCT05120271 Recruiting - Clinical trials for Hepatocellular Carcinoma

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

DUET-1
Start date: May 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.

NCT ID: NCT04794127 Recruiting - Clinical trials for Liposarcoma, Dedifferentiated

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

TRABEPIO
Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

This is a phase 2 study conducted in two sequential stages: The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who achieved a stable disease after a minimum of 4 cycles of T alone. If a minimum required activity will be demonstrated from the first stage, the second stage of the study will be conducted;otherwise, the study will be stopped. The second stage is an Italian open-label, multicenter, randomized, double arm, phase II trial, aimed at evaluating the combination of T and P in myxoid liposarcoma and G1 or G2 dedifferentiated liposarcomas compared to the standard treatment with T alone. Patients will be randomized with a 1:1 ratio to treatments arms as specified below: - Control arm (A): T alone - Experimental arm (B): T in combination with P

NCT ID: NCT04699292 Recruiting - Myxoid Liposarcoma Clinical Trials

International Prospective Registry on Local Treatment Approaches in MLS

Start date: January 18, 2021
Phase:
Study type: Observational [Patient Registry]

To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)

NCT ID: NCT04044768 Recruiting - Synovial Sarcoma Clinical Trials

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Start date: August 13, 2019
Phase: Phase 2
Study type: Interventional

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .